Država: Kanada
Jezik: angleščina
Source: Health Canada
PRUCALOPRIDE (PRUCALOPRIDE SUCCINATE)
PHARMASCIENCE INC
A06AX05
PRUCALOPRIDE
2MG
TABLET
PRUCALOPRIDE (PRUCALOPRIDE SUCCINATE) 2MG
ORAL
100
Prescription
MISCELLANEOUS GI DRUGS
Active ingredient group (AIG) number: 0153049002; AHFS:
APPROVED
2020-06-05
_pms-PRUCALOPRIDE – Product Monograph_ 1 of 37 _ _ PRODUCT MONOGRAPH PR PMS-PRUCALOPRIDE Prucalopride Tablets 1 mg and 2 mg Prucalopride as Prucalopride Succinate House Standard Prokinetic agent PHARMASCIENCE INC. Date of Approval: 6111 Royalmount Ave., Suite 100 June 3, 2020 Montréal, Québec H4P 2T4 www.pharmascience.com Submission Control No: 223701 _pms-PRUCALOPRIDE – Product Monograph_ 2 of 37 _ _ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION ............................................................ 3 SUMMARY PRODUCT INFORMATION .................................................................................. 3 INDICATIONS AND CLINICAL USE ........................................................................................ 3 CONTRAINDICATIONS ............................................................................................................. 4 WARNINGS AND PRECAUTIONS ............................................................................................ 4 ADVERSE REACTIONS .............................................................................................................. 6 DRUG INTERACTIONS ............................................................................................................ 11 DOSAGE AND ADMINISTRATION ........................................................................................ 12 OVERDOSAGE .......................................................................................................................... 13 ACTION AND CLINICAL PHARMACOLOGY ...................................................................... 13 STORAGE AND STABILITY .................................................................................................... 17 SPECIAL HANDLING INSTRUCTIONS ................................................................................. 17 DOSAGE FORMS, COMPOSITION AND PACKAGING ....................................................... 17 PART II: SCIENTIFIC INFORMATION ...................................... Preberite celoten dokument